Compare NICE Ltd (NICE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Summit Therapeutics Inc — how do they compare? NICE Ltd trades at $94.34 (market cap $5.91B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| NICE | SMMT | |
|---|---|---|
Market Cap | $5.91B | $10.48B |
Sector | Technology | Health |
52-Week High | $170.37 | $29.32 |
52-Week Low | $83.15 | $13.05 |
Enterprise Value | $5.69B | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE trades at $101.34, up 1.19% today, with a bullish technical signal and strong support near $99. The stock shows solid fundamentals with a P/E of 12.02, net income margin of 17.57%, and consistent earnings beats in recent quarters. Recent news highlights enterprise AI deployments with Banco do Brasil and Sopra Steria, reinforcing growth in customer engagement solutions.
The outlook remains positive with a consensus price target of $123.33, representing 22% upside potential. Risks include competitive pressures in AI software and potential margin compression, but analyst sentiment is strongly bullish with no sell ratings. Institutional interest is supported by robust cash flow generation and strategic AI expansions.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
